| 0.9347 0.007 (0.77%) | 03-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.87 |
1-year : | 20.18 |
| Resists | First : | 11.02 |
Second : | 17.27 |
| Pivot price | 15.25 |
|||
| Supports | First : | 0.89 |
Second : | 0.74 |
| MAs | MA(5) : | 13.2 |
MA(20) : | 15.52 |
| MA(100) : | 12.92 |
MA(250) : | 16.38 |
|
| MACD | MACD : | -0.7 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 31.3 |
D(3) : | 38.1 |
| RSI | RSI(14): 12.7 |
|||
| 52-week | High : | 26.63 | Low : | 0.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FIXX ] has closed below the lower bollinger band by 43.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ FIXX ] is to continue within current trading range. It is unclear right now based on current values. 299.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.97 - 0.98 | 0.98 - 0.98 |
| Low: | 0.89 - 0.89 | 0.89 - 0.9 |
| Close: | 0.93 - 0.94 | 0.94 - 0.94 |
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Sun, 07 Apr 2024
Analyzing Homology Medicines (NASDAQ:FIXX) & Apellis Pharmaceuticals (NASDAQ:APLS) - Defense World
Wed, 27 Mar 2024
Homology Medicines Transforms into Q32 Bio Inc. Post-Merger - TipRanks.com - TipRanks
Wed, 20 Mar 2024
Homology Medicines approves 1-for-18 reverse stock split By Investing.com - Investing.com
Fri, 26 Jan 2024
HOMOLOGY MEDICINES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick ... - PR Newswire
Wed, 03 Jan 2024
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency - Yahoo Finance
Wed, 27 Dec 2023
Latham Watkins Advises Homology Medicines in Merger Agreement With Q32 Bio - Latham & Watkins LLP
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.04e+006 (%) |
| Held by Institutions | 9.2 (%) |
| Shares Short | 18 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.057e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 884.9 % |
| Return on Equity (ttm) | -36.5 % |
| Qtrly Rev. Growth | 1.16e+006 % |
| Gross Profit (p.s.) | -2795 |
| Sales Per Share | -3667.5 |
| EBITDA (p.s.) | -4.757e+009 |
| Qtrly Earnings Growth | -35.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -96 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 18820 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|